Colleges to face criminal cases if they fail to return students’ documents

Mangaluru, Feb 25: Notorious gangster Ravi Poojary,

who has been extradited to India from Senegal, has 34 cases registered against him within the city police commissionerate.

Now in Bengaluru police custody for interrogation in connection with several cases there, Poojary faces cases relating to murder, murder attempt, extortion and threat calls in the city, police sources said.

Sources said the city police are trying to get Pujari for interrogation though it would take a while as the court has allowed Bengaluru police to keep him in custody for questioning and evidence taking for 15 days.

Most of the cases in the city against him, 28 of them, are in connection with threat calls.

He had allegedly made threat calls in 2015 to the then state ministers B Ramanath Rai and Abhayachandra Jain, demanding immediate arrest of the accused in the murder of Bajrang Dal worker Prashanth Poojary.

All the cases against Poojary in the city were registered between 2007 and 2018.

Cases involving murder, death threats and shootouts are among the cases to be investigated, the sources said.

A total of 28 cases of death threat calls, one of murder, three of shootouts, one of abduction and a case of funding his associates lodged in prison are the crimes being probed by the city police.

The cases are now pending in courts at different stages of trial.

Cases of making threat calls to businessmen using his associates demanding protection money have been registered at Moodbidri, Kavoor, Kadri, Konaje, Barke and Urwa police stations.

Some of his associates were imprisoned in 2012 in connection with threat calls to a businessman from Kinnigoli.

The case relating to providing them money while in prison was also registered in the same year.

Pujari, wanted in many cases including extortion and murder in different parts of the country, including Karnataka and who had been on the run for over 15 years, was deported to Senegal following his arrest and later extradited

He had jumped bail in Senegal last year after being arrested there.

Bengaluru, May 22: The Karnataka government, which has fixed Rs 200 as fine for not wearing masks and covering faces to contain coronavirus spread, has collected Rs 3.43 lakh from 15,000 people as fine from May 5 till date.

"From May 5, the government has collected Rs 3,43,000 by fining 1,715 citizens for nor wearing masks or covering their faces," the Bruhat Bengaluru Mahanagar Palike (BBMP) Commissioner said in a statement.

Here is a zone-wise chart showing fines that have been collected:

Meanwhile, Karnataka Medical Education Minister Dr K Sudhakar said the state has reached its target of scaling up to 10,000 tests per day by conducting 11,499 tests on Thursday. In Kalaburagi, where the first COVID-19 case was confirmed in the State, conducted over 1000 tests yesterday.

"By conducting 11,449 COVID-19 tests yesterday, we reached our target of scaling up to 10,000 tests per day Kalaburagi that saw the first COVID-19 case in the state conducted over 1000 tests yesterday," Sudhakar said.

As per the Union Health Ministry, Karnataka has 1,605 positive cases, of which 571 have been recovered and discharged and 41 have succumbed to the infection.

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.